Skip to main content

Table 3 Mixed-effects linear regressions predicting the change in CoV of stride time (n = 240 measures and n = 120 participants)

From: Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study

  Change in CoV of stride time*
Model 1† Model 2†
β 95% CI P-value β 95% CI P-value
Drugs effect       
     Use of CEIs −0.067 [−0.381; 0.246] 0.674 −0.193 [−0.512; 0.125] 0.234
     Use of memantine 0.179 [−0.138; 0.496] 0.268 −0.014 [−0.341; 0.313] 0.933
Time effect‡ 0.019 [−0.232; 0.269] 0.885 0.019 [−0.222; 0.259] 0.878
Drugs x time interaction       
     No treatment Ref Ref
     Use of CEIs 0.186 [−0.153; 0.526] 0.282 0.190 [−0.138; 0.518] 0.256
     Use of memantine −0.385 [−0.728; -0.415] 0.028 −0.371 [−0.702; -0.041] 0.028
Age     0.000 [−0.000; 0.000] 0.811
Female gender     −0.229 [−0.453; -0.004] 0.046
BMI     −0.0004 [−0.0000; 0.0008] 0.053
Number of drugs daily taken¶     0.011 [−0.019; 0.041] 0.490
Use of psychoactive drugs#¶     0.081 [−0.278; 0.116] 0.422
MMSE score¶     −0.028 [−0.046; -0.009] 0.003
Walking speed¶     −0.003 [−0.006; 0.0001] 0.147
  1. CI = confidence interval; CEIs: acetylcholinesterase inhibitors; BMI: body mass index; MMSE: Folstein's Mini-Mental State Examination; CoV: coefficient of variation; β: coefficient of regression beta corresponding to change in CoV of stride time; *: normalized by taking the square-root and coded as a continuous variable; †: separated models (Model 1: non-adjusted on baseline characteristics; Model 2: full adjusted model); ‡: time between before and after introduction of anti-dementia drugs; #: benzodiazepines, antidepressants or neuroleptics at baseline assessment; ¶: at baseline assessment (i.e., before treatment); P-value significant (i.e., P < 0.05) indicated in bold.